Panoramica dell'azienda
Emergent BioSolutions Inc. operates as a life sciences entity dedicated to providing comprehensive preparedness and response solutions against accidental, deliberate, and naturally occurring public health threats across the United States, Canada, and international markets. The company functions within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which focuses on the development and production of specialized pharmaceutical products and vaccines. The organization employs approximately 900 individuals and holds a market capitalization of $437.46M, while generating total revenue of $742.90M over the trailing twelve months. These financial dimensions indicate a mid-sized enterprise with a substantial revenue base that supports its operational capabilities, yet the market valuation suggests the company is currently priced at a level that reflects specific market conditions rather than a large-cap dominance.
Salute finanziaria
The company reported a trailing twelve-month revenue of $742.90M, with a corresponding net income of $52.60M and an EBITDA of $208.90M. The significant disparity between the revenue figure and the net income reveals a cost structure where operating expenses, including research, development, and administrative costs, consume a large portion of top-line growth before reaching the bottom line. However, the free cash flow stands at $205.39M, which demonstrates strong financial flexibility by indicating that the company generates substantial cash from operations even after accounting for capital expenditures. The gross margin sits at 49.4%, reflecting efficient production and pricing power in its specialty product lines, whereas the operating margin is negative at -15.2%, signaling that high fixed costs or specific period expenses are currently outweighing operating profitability. The profit margin stands at 7.1%, which represents the final net earnings relative to revenue after all expenses, interest, and taxes have been deducted. On the balance sheet, the company holds $205.40M in cash against total debt of $583.70M, resulting in a debt-to-equity ratio of 111.69%, which indicates a highly leveraged financial position where debt significantly exceeds equity capitalization. Despite this leverage, the current ratio of 5.01 suggests robust short-term liquidity, as current assets are five times greater than current liabilities, providing ample buffer against immediate obligations. Furthermore, the return on equity is 10.5% and the return on assets is 5.3%, metrics that reveal how effectively management utilizes shareholder equity and total assets to generate profits, respectively.
Valutazione del valore
The trailing twelve-month P/E ratio is 9.09, while the forward P/E is 2.83, implying that the market expects a dramatic increase in future earnings that would justify a significant compression in the current valuation multiple. The price-to-book ratio is 0.84, indicating that the stock trades at a discount relative to its book value, suggesting the market may be pricing in risks or expecting normalization in asset values. Alternative valuation metrics such as the price-to-sales ratio of 0.59 and an EV/EBITDA of 3.90 suggest the company is valued on a very low multiple basis compared to historical averages or peers, often seen in cyclical or distressed turnaround scenarios. The 52-week price range spans from a low of $4.02 to a high of $14.06, and without the specific current share price listed in the provided facts, the exact percentage deviation from the high cannot be calculated; however, the wide spread between the 52-week high and low of $10.04 demonstrates substantial price volatility. The beta value is 2.36, which means the stock exhibits high sensitivity to market movements and is expected to fluctuate with greater intensity than the broader market index, characteristic of smaller-cap biotechnology or specialty drug manufacturers.
Growth & Income
The revenue growth year-over-year is -23.6%, while the earnings growth is listed as N/A due to a lack of comparable prior year data in the provided facts. The negative revenue growth indicates a contraction in sales, which naturally constrains earnings potential, and the absence of a calculated earnings growth rate suggests that profitability metrics are either volatile or not expanding at a rate faster than the shrinking revenue base. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that the organization retains all of its earnings to fund operations, research, or debt reduction rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by a non-dividend strategy in the face of declining revenue, forcing reliance on organic business development or asset monetization to drive future value creation.